RBTQ Stock Chart & Stats
€1.25
€0.00(0.00%)
At close: 4:00 PM EDT
€1.25
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.13 - €2.48
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€30.90M
Enterprise Value€71.31M
Total Cash (Recent Filing)€10.33M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Dec 11, 2026EPS Estimate
-0.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.69
Shares Outstanding13,511,531
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)1.13
Price to Sales (P/S)0.00
P/FCF Ratio-1.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-1.84
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-light Balance SheetEffectively zero debt reduces solvency risk and avoids interest obligations while Edesa funds clinical development. This gives the company more financial flexibility than a similarly loss-making biotech with meaningful leverage, although it does not remove the need for future funding.
Expanded EB06 Clinical OpportunityFDA clearance expands the addressable recruitment base for EB06 and allows U.S. sites to participate in the vitiligo Phase 2 study. Broader enrollment infrastructure can improve trial execution and generate a more informative data set for evaluating the candidate.
Targeted Pipeline MechanismEB06’s targeted CXCL10 mechanism gives Edesa a differentiated scientific rationale within inflammatory and immune-related disease development. If clinical results support the approach, this distinction could strengthen the candidate’s positioning in vitiligo and related unmet medical needs.
Bears Say
No Operating RevenueZero revenue means Edesa has not yet established commercial operations or an income stream to offset research spending. Persistent, sizable losses leave results dependent on clinical progress and financing rather than customer demand, limiting operating leverage over the next several quarters.
Persistent Cash BurnOngoing negative operating and free cash flow shows that reported losses translate into actual cash consumption. Continued development therefore requires external capital, creating funding dependence and potentially constraining the pace or scope of clinical programs if financing conditions become less supportive.
Volatile Equity And Poor Capital ReturnsLarge swings in equity alongside deeply negative return on equity indicate that invested capital has not generated profits and that the financial base is unstable. This weak capital efficiency can increase reliance on financing activity and dilute the benefits of successful development spending.
Edesa Biotech News
RBTQ FAQ
What was Edesa Biotech Inc’s price range in the past 12 months?
Edesa Biotech Inc lowest stock price was €1.13 and its highest was €2.48 in the past 12 months.
What is Edesa Biotech Inc’s market cap?
Edesa Biotech Inc’s market cap is €30.90M.
When is Edesa Biotech Inc’s upcoming earnings report date?
Edesa Biotech Inc’s upcoming earnings report date is Dec 11, 2026 which is in 53 days.
How were Edesa Biotech Inc’s earnings last quarter?
Edesa Biotech Inc released its earnings results on Aug 13, 2026. The company reported -€0.534 earnings per share for the quarter, missing the consensus estimate of -€0.387 by -€0.147.
Is Edesa Biotech Inc overvalued?
According to Wall Street analysts Edesa Biotech Inc’s price is currently Overvalued.
Does Edesa Biotech Inc pay dividends?
Edesa Biotech Inc does not currently pay dividends.
What is Edesa Biotech Inc’s EPS estimate?
Edesa Biotech Inc’s EPS estimate is -0.52.
How many shares outstanding does Edesa Biotech Inc have?
Edesa Biotech Inc has 13,511,531 shares outstanding.
What happened to Edesa Biotech Inc’s price movement after its last earnings report?
Edesa Biotech Inc reported an EPS of -€0.534 in its last earnings report, missing expectations of -€0.387. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Edesa Biotech Inc?
Currently, no hedge funds are holding shares in DE:RBTQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Edesa Biotech Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:RBTQ Sentiment 100%
Sector Average 67%
Sector Average 67%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.47%
12-Months-Change
Fundamentals
Return on Equity
-124.21%
Trailing 12-Months
Asset Growth
-14.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Edesa Biotech Inc
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3 clinical trial for acute respiratory distress syndrome (ARDS) in COVID-19 patients, and EB01, a topical therapy in a Phase 2B clinical study addressing chronic allergic contact dermatitis. Furthermore, Edesa has a licensing collaboration with NovImmune SA to advance monoclonal antibodies specifically designed to target TLR4 and CXCL10. This company was established in 2015 and is based in Markham, Canada.
Technical Analysis
Instil Bio
―
TScan Therapeutics
―
MiNK Therapeutics
―
Xilio Therapeutics
―
Tevogen Bio Holdings
―